Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, Tanaka K, Otsubo K, Inoue H, Yoneshima Y, Iwama E, Arimura-Omori M, Harada E, Hamada N, Okamoto I, Nakanishi Y. Suzuki K, et al. Among authors: otsubo k. Int Immunol. 2020 Jul 28;32(8):547-557. doi: 10.1093/intimm/dxaa022. Int Immunol. 2020. PMID: 32253426
PICT1 expression is a poor prognostic factor in non-small cell lung cancer.
Okamura K, Takayama K, Kawahara K, Harada T, Nishio M, Otsubo K, Ijichi K, Kohno M, Iwama E, Fujii A, Ota K, Koga T, Okamoto T, Suzuki A, Nakanishi Y. Okamura K, et al. Among authors: otsubo k. Oncoscience. 2014 May 25;1(5):375-82. doi: 10.18632/oncoscience.43. eCollection 2014. Oncoscience. 2014. PMID: 25594032 Free PMC article.
Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
Sakata S, Saeki S, Okamoto I, Otsubo K, Komiya K, Morinaga R, Yoneshima Y, Koga Y, Enokizu A, Kishi H, Hirosako S, Yamaguchi E, Aragane N, Fujii S, Harada T, Iwama E, Semba H, Nakanishi Y, Kohrogi H. Sakata S, et al. Among authors: otsubo k. Lung Cancer. 2016 Sep;99:41-5. doi: 10.1016/j.lungcan.2016.06.009. Epub 2016 Jun 14. Lung Cancer. 2016. PMID: 27565912 Clinical Trial.
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I. Otsubo K, et al. Cancer Sci. 2017 Sep;108(9):1843-1849. doi: 10.1111/cas.13309. Epub 2017 Jul 26. Cancer Sci. 2017. PMID: 28667792 Free PMC article. Clinical Trial.
Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A, Kato T, Atagi S, Horinouchi H, Ando M, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakanishi Y, Okamoto I. Otsubo K, et al. Clin Lung Cancer. 2018 Jan;19(1):e5-e9. doi: 10.1016/j.cllc.2017.06.003. Epub 2017 Jun 20. Clin Lung Cancer. 2018. PMID: 28687482
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I. Tanaka K, et al. Among authors: otsubo k. Oncotarget. 2017 Jul 12;8(40):68123-68130. doi: 10.18632/oncotarget.19243. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978102 Free PMC article.
314 results